Mabwell Therapeutics, Inc.
Mabwell Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, is at the forefront of innovative therapeutic solutions. Founded in 2016, Mabwell focuses on the research, development, and commercialisation of monoclonal antibodies and other biologics, primarily targeting oncology and autoimmune diseases. With a strong presence in both the US and China, Mabwell has achieved significant milestones, including the successful development of unique antibody therapies that address unmet medical needs. Their core products stand out due to their advanced engineering and specificity, positioning the company as a notable player in the global biopharmaceutical landscape. Mabwell's commitment to scientific excellence and patient-centric solutions underscores its reputation as a trusted name in the industry.
DitchCarbon Score
How does Mabwell Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mabwell Therapeutics, Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mabwell Therapeutics, Inc.'s reported carbon emissions
Mabwell Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years. As such, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that Mabwell Therapeutics has not outlined any specific reduction targets or commitments related to climate action. This lack of publicly stated initiatives may reflect a broader industry context where many biopharmaceutical companies are increasingly focusing on sustainability and carbon neutrality. As the industry evolves, it is anticipated that Mabwell Therapeutics may develop and disclose more comprehensive climate commitments and reduction strategies in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mabwell Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
